these murine models may accelerate vascular plaque development resulting in advanced lesions within several weeks. 3, 4 Consequently, such models have been crucial in understanding the murine molecular and cellular basis of atherosclerosis. Yet, the relevance in human atherosclerotic disease remains elusive for several reasons. Primarily, the morphology of atherosclerotic plaque in mice differs from that of humans and acute events because of luminal thrombosis and evident plaque rupture are rarely observed. Second, clinical disease manifestations such as coronary artery disease (CAD) or ischemic stroke in mice are rare or lacking. Third, it is arguable whether complete knockouts in mice correspond with expression-changing mutations in humans. Finally, despite the knockout of individual genes, genetic redundancy on the pathway level further complicates the interpretation of results from animal models. 5 In recent years, millions of common single-nucleotide polymorphisms (SNPs) in the human genome were identified, and our understanding of these variants with respect to the genomic architecture has increased significantly. 6 This has opened up the possibility to agnostically assess the effects of genome-wide variation on human traits and disease. 7 Indeed, meta-analyses of human genome-wide association studies (GWAS) have identified many risk loci for CAD 8 and large artery ischemic stroke (LAS). 9 These GWAS provide the unique opportunity to validate the putative disease-causing genes identified through murine models in humans.
We performed a systematic review to identify atherosclerosis-causing genes in mice and carried out gene-based association tests of their human orthologs for CAD and LAS. Moreover, we investigated the association of these genes with human atherosclerotic plaque characteristics. Furthermore, we assessed whether there are tissue-specific cis-acting expression quantitative trait loci (eQTLs) for the genes in humans. We report that putative atherosclerosis-causing genes reveal little association with human CAD, LAS, or atherosclerotic plaque characteristics, despite the fact that the majority of these genes have cis-acting eQTLs.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Of the 659 murine genes ( Table I in the online-only Data Supplement), a total of 486 genes (73.75%) were studied in knockout mice, 57 genes (8.65%) were studied in transgenic mice, and 116 genes (17.60%) were targeted by specific compounds ( Table I in 
Validation Within GWAS of CAD and LAS
We obtained summary statistics from GWAS on CAD 8 and large artery stroke 9 for SNPs ±50 kb from the 5′ and 3′ gene borders of the 659 studied murine genes (online-only Data Supplement). We used these as input for a gene-based analysis using versatile gene-based association study (VEGAS), which assigned an empirical P value (after permutations) to each of the 659 genes based on the P value of the SNPs in and ±50 kb around the genes of interest. 10 Thus, each gene was given a P value of association to CAD or LAS based on the GWAS results while taking into account the correlation between SNPs that may exist. Of the 659 studied genes that have been shown to affect atherosclerotic phenotypes in mice, 11 (1.7%) genes were associated with CAD after correction for multiple testing (P≤0.05/659≤7.59×10 −5 , Table III in the online-only Data Supplement). In contrast, none of the genes were associated with LAS after correction for multiple testing. The top 10 most significant genes for CAD and LAS are shown in Table  1 . A total of 84 (12.7%) and 41 (6.2%) of the genes were associated with CAD and LAS, respectively, at a nominal P≤0.05. The overlap of associated genes between LAS and CAD is limited; only the locus at 9p21 (containing CDKN2A/B), significantly associated with CAD, was also nominally associated with LAS (P<0.0062). We did not observe any further overlap between CAD and LAS top-associated genes. When looking at model groups to which the genes were assigned (knockout, transgenic, or compound), we did not observe significant differences between groups for the 11 significant genes (P=0.513 using a χ 2 test).
Validation Using Human Atherosclerotic Plaque
Subsequently, we conducted a similar gene-based analysis using VEGAS on 7 plaque characteristics in the Athero-Express Biobank Study. 11 These human plaque characteristics have previously been associated with clinical presentation 12 and have been examined in many atherosclerotic murine models. Overall, of the 657 genes a low number of genes nominally associated with a human plaque characteristic and followed the expectation under the null (range, 4.1%-6.1%, Table V in the online-only Data Supplement). Only 2 genes were significantly associated with human intraplaque macrophages, F10 on chromosome 13 (P=1.00×10 −6 ), and TNFAIP8L2 on chromosome 1 (P=5.80×10 −5 ) after correction of multiple testing. All gene-based association results for the 659 target genes with plaque characteristics are provided in Table VI in the online-only Data Supplement.
Validation Using Pathway Analyses
The genes that reached nominal significance in the gene-based analysis of CAD and LAS were further analyzed using ingenuity to identify canonical pathways associated with CAD and LAS (Table IV in the online-only Data Supplement). Table  2 provides the 25 most significant canonical pathways based on the 659 murine target genes and the translation of these genes to human CAD and LAS. The liver X receptor/retinoid X receptor (LXR/RXR) activation pathway (involved in lipid metabolism) that has been extensively studied in atherosclerotic mice was found to be significantly enriched for genes associated with CAD and LAS. In contrast, the nuclear factor κB (NFκB) inflammatory signaling pathway that has been extensively studied in murine models, revealed less genes that associated with CAD or LAS ( Table 2) . Another example is the T-lymphocyte differentiation pathway that has been extensively studied in mice and associated with murine atherosclerosis, but for which we found little supportive evidence in our gene-based analysis associating with human CAD or LAS.
eQTL Analysis of the Murine Genes
In murine models, the 659 genes are clearly affected through knockout, transgenic techniques, or targeted compound treatment. A close human analog of such an effect would be cisacting common genetic variants, affecting gene expression through reducing or upregulating expression. Such variants are known as eQTLs. We conducted cis-eQTL analyses using the Stockholm Atherosclerosis Gene Expression (STAGE) study and queried 3 online public resources ( Table VII in the online-only Data Supplement) to identify common variants modulating the expression of the 659 genes in humans. Across the 4 data sets and 11 cell/tissue types, we found eQTLs (P≤7.31×10 −7 after correction for 68 402 variants in and around these genes) for 411 of the 659 genes (these genes are marked orange in Table VIII in the online-only Data Supplement). For all genes, we found SNPs in cis-affecting expression (P<0.05) in any of the 4 data sets queried (Table  VIII in the online-only Data Supplement). In a representative example of a canonical pathway (NFκB), we show that each target gene has a cis-eQTL, that is, a common variant (SNP) in or around the gene that has a significant effect on tissuespecific gene expression in humans. Not all genes will exert their effect on clinical outcome via gene expression, rather gene function. Thus, we compared the gene-based association results for CAD and LAS for the genes with a valid eQTL (P eQTL <7.31×10 −7 ) and without (P eQTL ≥7.31×10 −7 ), but found no significant difference in enrichment for disease association in either CAD (P=0.882) or LAS (P=0.634). Similarly, we compared the gene-based association results between the model groups for the 84 and 42 genes that associated with CAD and LAS (knockout, transgenic, or compounds) and found a statistical difference between groups for CAD (P=0.0013, χ 2 =13.291). A pairwise comparison of the 3 model groups revealed that knockout and compounds do not have statistically different gene-based results (P=0.718), whereas the results between knockouts and transgenic mice (P=0.00049, χ 2 =12.146) or transgenic mice and compounds do (P=0.0029, χ 2 =8.852). We found no statistical difference for LAS (P=0.637) when comparing the 3 model groups. We also stratified our pathway analyses based on these 3 model groups, but this revealed no additional significant pathways. CARDIoGRAM: meta-analysis of genome-wide association studies (GWAS) of CAD. METASTROKE: meta-analysis of GWAS of LAS. Results are given per gene with its chromosomal (chr) start and end base pair position. n single-nucleotide polymorphisms (SNPs): number of SNPs studied for that gene. Also given are the most significant (best) SNP for that gene and its P value. CAD indicates coronary artery disease; and LAS, large artery ischemic stroke. * indicates P values for genes with Bonferroni corrected P gene ≤7.59×10 −5 , and † for genes with nominal P<0.05. Downloaded from http://ahajournals.org by on April 9, 2020
Discussion
This study shows that putative atherosclerosis-causing genes identified in murine atherosclerosis models reveal little association with human CAD, LAS, or atherosclerotic plaque characteristics, despite the fact that the majority of these genes have cis-acting eQTLs.
Overall, the majority of genes associated with an atherosclerotic phenotype in mice do not carry variants that associate with human CAD, LAS, or advanced plaque characteristics.
In contrast, murine genes involved in lipid metabolism significantly associated with human CAD, which is consistent with the known role of lipids in CVD risk. Indeed, lipid-lowering drugs, such as statins, act through HMGCR (chromosome 5q13.3) to lower circulating lipids. 13 A recent GWAS showing that variants in the HMGCR locus are associated with an increase of 2.84 mg/dL total cholesterol, 14 effectively confirmed this drug action retrospectively. However, for most murine genes and pathways of innate and adaptive immunity, For each ingenuity canonical pathway, the number and percentage of murine genes overlapping with the total number of pathways was determined (Overlap). For coronary artery disease (CARDIoGRAM) and large artery stroke (METASTROKE) the number of murine genes reaching P≤0.05 (n genes P≤0.05) for association with the respective disease is given. P indicates the binomial P value and represents the proportion of murine genes associated with the disease compare with the total number of murine genes. For all murine genes the total n genes P≤0.05 and n genes P>0.05 for association with either disease is given. eNOS indicates endothelial nitric oxide synthase; IL, interleukin; LPS, lipopolysaccharide; LXR, liver X receptor; PPAR, peroxisome proliferator-activated receptor; RXR, retinoid X receptor; TR, thyroid hormone receptor; and VEGF, vascular endothelial growth factor.
there was no association with human CAD, LAS, or plaque characteristics.
ApoE −/− and LDLR −/− models are widely used to study the initiation and progression of atherosclerosis. To study the effect on plaque development 15 or therapeutic strategies, 16 additional (double) knockout or transgenic atherosclerotic models have been developed. Yet, they lack plaque rupture thrombosis and subsequent cardiac or cerebral ischemia. Although therapeutic strategies have been developed based on animal models, failures in clinical utilization underscores the need for human verification and translation before initiating targeted drug development programs. 17, 18 Indeed, a post hoc analysis by deCODE genetics and Amgen assessed the validity of results from human genetic studies as positive predictors of successful clinical trials. 19 Essentially all failed clinical trials targeting a gene (locus) lack any evidence from genetic association studies. 19 There are several potential explanations for the observed discrepancies of genes involved in atherosclerotic murine studies and human cardiovascular disease. First, they may be explained by differences in effect sizes. Common genetic variants associated with human disease often have a modest effect, in contrast to experimental gene manipulation (ie, knockout) in animal models to study atherosclerotic disease. These genetic modifications in mice limit inferences about dose-dependent effects, which is relevant for predicting drug effects in human disease. Furthermore, the combined effect of human population history and selection may have yielded little functional genetic variation and thus no association with CAD or LAS, even in a large sample. The low number of murine genes associated with plaque characteristics in the Athero-Express study may be explained by limited sample size and, therefore should be interpreted with caution. However, for our gene-based analysis of CAD and LAS, we had access to GWAS results based on large meteanalyses, providing substantial statistical power to detect genes associated with disease. In addition, we studied the enrichment of murine-derived atherosclerosis-related gene sets within canonical pathways. We then tested whether their human orthologs (that were nominally associated with disease based on a gene-based test) were also observed in these pathways. For the majority of pathways, weak or even absent evidence was found in humans. Of note is the LXR pathway which is proven to be linked with human cardiovascular disease, and for which we found ample evidence using our gene-based and our pathway analysis. Furthermore, in atherosclerotic mouse models, plasma lipid levels are the main determinant of lesion development. The associations between mice and human GWAS studies may improve when human individuals are studied with (genetic) susceptibility to abnormal lipid metabolism. Such interactions have not been explored in this study. However, such an association would imply that the atherosclerotic mouse models cannot represent disease development in the general population.
Second, one might argue that the SNP to gene mapping done by VEGAS is conservative and consequently excludes (regulatory) variants of greater effect that may lie as far as 1 Mb. However, most variants significantly affecting gene expression are found within 50 kb of the gene body, 20 and regulatory elements are usually found in intergenic regions. Nevertheless, it is unlikely that erroneous annotations alone can explain the strong discrepancy between murine genes and their human orthologs within pathways.
Third, undoubtedly the Ingenuity Knowledge Base is a comprehensive summary of the current knowledge from literature on gene networks and pathways. Although it is constantly updated and manually curated, our ingenuity-based pathway analysis is biased. Indeed, genes (and thereby networks and pathways) that are not studied (in humans or any model system) would simply not exist in ingenuity, thus partly explaining an apparent discrepancy between associated pathways in humans and mice. In addition, pathways are often cell and organ specific and a selective approach toward cell types that are considered to play a dominant role in atherogenesis may affect the readout of our pathway analyses.
Fourth, the annotation of candidate genes to GWAS loci is usually based on literature and proximity to the genomewide significant SNP, but whether such a gene actually influences disease is still unknown. For our gene-based approach, we mapped the mouse genes to their human ortholog and tested their association with CAD or LAS. Therefore, the genes that have been annotated to GWAS loci may not seem in our results even when the SNPs in their proximity meet the genome-wide significance threshold.
Finally, a transgenic or compound-treated mouse may not be comparable with a knockout model, thus explaining the lack of association of these genes with human disease. Given the statistically different gene-based results, we stratified our pathway analyses based on these 3 different model types and found no difference. Hence, it is unlikely that the type of murine intervention model explains the lack of association with human disease.
Previous studies have raised doubts on the validity of translating murine models to human pathophysiology in studying immune responses, [21] [22] [23] although conflicting results have been obtained. 24 Our study adds to the debate on the relevance of murine models for human atherosclerotic disease and supports the view that the direction of the scientific process matters. The lack of association of murine atherosclerotic genes with human CAD, LAS, or human plaque characteristics may be because of diverged gene expression patterns among mice and humans resulting in different phenotypic effects. Indeed, results from the recently published Mouse ENCODE (Encyclopedia of DNA elements) project show that gene expression patterns diverge between mice and humans. 25, 26 Moreover, phenotypic effects of orthologous genes frequently differ between species. This suggests that a sensible approach would be to group genes based on mouse-human orthology to improve the translational power of putative murine genes. GWAS agnostically provide human evidence for the involvement of genetic loci in the underlying mechanisms of atherosclerotic disease, including CAD and LAS. Therefore, from the outset, the rationale to initiate an examination of the role of genes in these loci in murine models of atherosclerosis could be supported by human data.
Our study may have several limitations. Individuals of non-European descent are underrepresented in the GWAS we examined. It remains to be investigated if results will differ for GWAS in non-European cohorts.
The genetic association study on human plaque characteristics was executed in the Athero-Express study and included 1443 patients with significant atherosclerosis. Although this study represents the largest collection of histologically investigated plaques, this study may have limited power when examining the genetics of plaque characteristics.
We studied all published papers that applied the ApoE −/− and LDLR −/− as a model for atherosclerosis. However, alternative murine models have been studied in atherosclerotic disease that we did not include in our search and we cannot exclude that these reveal better associations with the human genetic outcome studies.
In conclusion, a role for genes that has been observed in mice for atherosclerotic lesion development could scarcely be confirmed studying associations of disease development with common human genetic variants indicating that knockout models of atherosclerosis are not a good reflection of the variation that underlies common forms of atherosclerosis. The value of murine atherosclerotic models for selection of therapeutic targets in human disease remains unclear.
